US OptionsDetailed Quotes
ESPR241220C3000
- 0.04
- -0.01-20.00%
15min DelayClose Dec 13 16:00 ET
0.05High0.04Low
0.05Open0.05Pre Close49 Volume2.26K Open Interest3.00Strike Price241.00Turnover198.24%IV35.11%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1525Delta0.4200Gamma56.25Leverage Ratio-0.0113Theta0.0000Rho8.58Eff Leverage0.0007Vega
Esperion Therapeutics Stock Discussion
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet